OPA1 Antibody (1088319) [Unconjugated]

Western Blot shows lysates of MCF‑7 human breast cancer cell line and MDA‑MB‑231 human breast cancer cell line. PVDF membrane was probed with 2 µg/ml of Mouse Anti-Human OPA1 Monoclonal Antibody (Catalog # MAB11631) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). Specific bands were detected for OPA1 at approximately 80 and 100 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

OPA1 was detected in immersion fixed paraffin-embedded sections of human kidney using Mouse Anti-Human OPA1 Monoclonal Antibody (Catalog # MAB11631) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the mitochondrial membrane. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Simple Western shows lysates of MDA‑MB‑231 human breast cancer cell line, loaded at 0.5 mg/ml. A specific band was detected for OPA1 at approximately 90 kDa (as indicated) using 100 µg/mL of Mouse Anti-Human OPA1 Monoclonal Antibody (Catalog # MAB11631). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

• Reactivity: Hu
• Applications: WB, Simple Western, IHC
• Clone: 1088319
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

OPA1 Antibody (1088319) [Unconjugated] Summary

• Immunogen: Synthetic Peptide
  Accession # O60313
• Specificity: Detects a synthetic peptide specific for human OPA1 around amino acid 200 in Direct ELISA.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 3-25 ug/mL
  • Simple Western 100 ug/mL
  • Western Blot 2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Reconstitution Instructions: Reconstitute lyophilized material at 0.2 mg/ml in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for OPA1 Antibody (1088319) [Unconjugated]

• BERHS
• EC 3.6.5.5
• FLJ12460
• KIAA0567dynamin-like 120 kDa protein, mitochondrial
• LargeG
• lilr3
• MGM1
• mitochondrial dynamin-like GTPase
• MTDPS14
• NPG
• NPGlargeG
• NTG
• NTGmitochondrial dynamin-like 120 kDa protein
• OPA1
• optic atrophy 1 (autosomal dominant)
• Optic atrophy protein 1

Background

Optic Atrophy-1 (OPA1), aka Dynamin-like 120 kDa protein, mitochondrial, is a Dynamin-related GTPase required for mitochondrial fusion and regulation of apoptosis. OPA1 exists as a single-pass membrane protein in the mitochondrion inner membrane as well as in soluble forms in mitochondrion intermembrane space, and is expressed in retina, brain, testis, heart, skeletal muscles. Human OPA1 binds PARL and interacts with CHCHD3 as well as IMMT (preferentially with soluble OPA1 forms). Proteolytic processing in response to intrinsic apoptotic signals may lead to disassembly of OPA1 oligomers and release of the caspase activator cytochrome C (CYCS) into mitochondrial intermembrane space. OPA1 protein form S1 is an inactive form produced by cleavage at S1 position by metalloendopeptidase OMA1 following stress conditions that induce loss of mitochondrial membrane potential, leading to negative regulation of mitochondrial fusion. Defects in OPA1 have been linked to optic atrophy type 1 (OPA1) and dominant optic atrophy plus syndrome (DOA+).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • O60313()